Exact Sciences (EXAS): Among Billionaire George Soros' Small-Cap Stocks with Huge Upside Potential
We recently published a list of . In this article, we are going to take a look at where Exact Sciences Corporation (NASDAQ:EXAS) stands against Billionaire George Soros' other small-cap stocks with huge upside potential.
When a legendary investor like George Soros makes a move, Wall Street pays attention. However, most of the limelight is taken by mega-cap stocks, with no one paying heed to the many small-cap stocks that form an important part of Soros' portfolio.
Digging out these small-cap stocks is important. In some cases, these are the mega-cap stocks of the future. In other cases, these provide amazing returns in a very short period of time. The key is to get in early. And what better way to get in early than to do it when the big guys do.
We therefore decided to compile a list of stocks in billionaire George Soros' portfolio that have the most upside. To come up with our list of billionaire George Soros' 10 Small-Cap stocks with huge upside potential, we first looked at his top 50 stock holdings. We then filtered out the companies to look at only the ones with a market cap below $10 billion.
After arriving at his top small-cap holdings list, we then looked at the median analyst price targets on those stocks and then ranked them by their upside potential.
A research team in a laboratory discussing the results of a lab screening test for biomarkers.
Exact Sciences Corporation (NASDAQ:EXAS) operates as a cancer screening and diagnostic test products provider. The company provides Cologuard, Oncotype DX Breast DCIS Score Test, OncoExTra Test for tumor profiling, Riskguard Test, Oncotype DX Breast Recurrence Score Test, and Oncotype DX Colon Recurrence Score Test. According to the median analyst price target, the stock still has an upside of 47.23%.
On April 22, the firm announced the launch of its new test, Oncodetect. This new test detects the molecular residual disease (MRD) among multiple solid tumors. According to the company, this test provides clear results, 'detected' or 'not detected', along with the quantitative data to facilitate treatment.
Brian Baranick, Executive Vice President and General Manager Precision Oncology at Exact Sciences (NASDAQ:EXAS), said:
'Exact Sciences is transforming cancer care by delivering tests that provide the clarity patients and physicians need to make confident decisions,… Advanced detection tools like the Oncodetect test help bridge that gap by providing clinical insights at critical periods, leading to more informed treatment decisions and personalized care.'
RBC Capital Markets started coverage of Exact Sciences (NASDAQ:EXAS) last month. The research firm assigned a Sector Perform rating to the stock with a price target of $52, citing growth potential in the oncology screening sector of liquid biopsy.
Overall, EXAS ranks 8th on our list of billionaire George Soros' small-cap stocks with huge upside potential. While we acknowledge the potential of EXAS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than EXAS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
FuelCell Energy Inc (FCEL) Q2 2025 Earnings Call Highlights: Revenue Surge Amid Strategic ...
Total Revenue: $37.4 million, up from $22.4 million in the prior year quarter. Loss from Operations: $35.8 million, compared to $41.4 million in the prior year quarter. Net Loss Attributable to Common Stockholders: $38.8 million, compared to $32.9 million in the prior year quarter. Net Loss Per Share: $1.79, compared to $2.18 in the prior year quarter. Adjusted EBITDA: Negative $19.3 million, compared to negative $26.5 million in the prior year quarter. Cash, Restricted Cash, Cash Equivalents, and Short-term Investments: $240 million as of April 30, 2025. Product Revenues: $13 million, compared to no product revenues in the prior year period. Service Agreement Revenues: $8.1 million, up from $1.4 million in the prior year period. Generation Revenue: $12.1 million, down from $14.1 million in the prior year period. Advanced Technology Contract Revenues: $4.1 million, down from $6.9 million in the prior year period. Gross Loss: $9.4 million, compared to $7.1 million in the prior year quarter. Operating Expenses: Decreased to $26.4 million from $34.3 million in the prior year quarter. Backlog: Increased by approximately 18.7% to $1.26 billion from $1.06 billion as of April 30, 2024. Warning! GuruFocus has detected 5 Warning Signs with FCEL. Release Date: June 06, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. FuelCell Energy Inc (NASDAQ:FCEL) announced a restructuring plan to prioritize sales of its molten carbonate platform, aiming to accelerate the timeline to expected future profitability. The company is focusing on its core carbonate platform, which is aligned with the growing demand for distributed power generation in the US, Asia, and Europe. FuelCell Energy Inc (NASDAQ:FCEL) has formed a strategic partnership called Dedicated Power Partners (DPP) to accelerate the deployment of its carbonate FuelCell technology in data centers and other large-scale applications. The company reported a significant increase in total revenues for the second quarter of fiscal year 2025, reaching $37.4 million compared to $22.4 million in the prior year quarter. FuelCell Energy Inc (NASDAQ:FCEL) is committed to disciplined cost management, with a plan to reduce operating expenses by 30% on an annualized basis compared to fiscal-year 2024. FuelCell Energy Inc (NASDAQ:FCEL) is pausing broader solid oxide R&D, which may limit future innovation in this area. The company's Torrington manufacturing facility is currently operating at an annualized production rate of approximately 31 megawatts, well below the target of 100 megawatts needed for positive adjusted EBITDA. Despite narrowing losses, FuelCell Energy Inc (NASDAQ:FCEL) reported a net loss attributable to common stockholders of $38.8 million for the second quarter of fiscal year 2025. The restructuring plan includes a global workforce reduction and significant reduction of discretionary overhead spending, which may impact employee morale and operational capacity. Advanced technology contract revenues decreased to $4.1 million from $6.9 million, indicating potential challenges in this segment. Q: Can you provide an update on the Dedicated Power Partners (DPP) initiative and any momentum with customers and orders? A: Jason Few, President and CEO, explained that DPP is focused on data center customers, combining fuel from Diversified Energy, Fuelcell power generation, and financing through TESIAC. They are actively pursuing conversations in Northern Virginia and Kentucky and feel positive about the momentum in turning these discussions into transactions. Q: What is the timeline for reaching EBITDA neutrality, and what are the production targets? A: Michael Bishop, CFO, stated that achieving adjusted EBITDA positive is expected when the Torrington facility reaches 100 megawatts of production. Currently, the facility operates at 31 megawatts, and the timeline depends on the flow of orders. The facility has a capacity of 100 megawatts without additional capital expenditure and can expand to 200 megawatts with further investment. Q: How does the current focus on manufacturing impact the path to profitability compared to the generation portfolio? A: Michael Bishop noted that while the generation portfolio contributes to financials, the focus is on product and service sales. The company is not relying on increasing the generation portfolio but sees opportunities in selling products into DPP and other markets, including Korea, which will also include service agreements. Q: With the rising costs of gas turbines, how does this affect your pricing strategy for data center applications? A: Jason Few mentioned that the increased cost and timeline for gas turbines present an opportunity for Fuelcell Energy. They do not foresee significant changes in pricing to customers due to demand driven by electricity growth and intend to capitalize on this opportunity. Q: Can you elaborate on the power generation opportunities for AI and data centers and which customers are showing the most urgency? A: Jason Few highlighted that the opportunity is not solely around data centers but includes grid resiliency and reliability projects. The data center market is fragmented, with developers, hyperscalers, and gas distribution companies all showing interest. Fuelcell Energy is engaging with all these segments, focusing on delivering power blocks to get data centers operational. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Wall Street Journal
4 hours ago
- Wall Street Journal
Dow, S&P 500, Nasdaq All Positive on the Year Once Again
All three major U.S. stock indexes closed in positive year-to-date territory simultaneously for the first time since Feb. 21. The S&P 500, Nasdaq Composite, and Dow Jones Industrial Average all rose by 1%, or more, during Friday's trading. Stocks have been volatile through weeks of tariff news, but have recovered losses from recent months. This year, the S&P 500 is up 2%, the Nasdaq is up 1.1% and the Dow is up 0.5%, according to Dow Jones Market Data.
Yahoo
4 hours ago
- Yahoo
Alpha Cognition Inc. Common Stock (ACOG): A Bull Case Theory
We came across a bullish thesis on Alpha Cognition Inc. Common Stock (ACOG) by anygal on r/investing on Reddit. In this article, we will summarize the bulls' thesis on ACOG. Alpha Cognition Inc. Common Stock (ACOG)'s share was trading at $9.33 as of 30th May. ACOG's forward P/E was 26.88 according to Yahoo Finance. A chemist in a laboratory analyzing data from the various therapeutic tests conducted. Alpha Cognition Inc. (NASDAQ: ACOG) represents a potentially overlooked opportunity in the Alzheimer's treatment space, having recently launched its oral drug, Zunveyl, at the end of March. With a current market cap of $150 million and $45 million in cash, the company is targeting the underserved segment of the Alzheimer's population—specifically, the 50% of patients in long-term care (LTC) not taking any current medications due to severe side effects. Unlike other galantamine-based drugs, Zunveyl significantly slows disease progression and improves short-term memory with a markedly better safety profile—only one serious side-effect case was reported in its Phase 3 trials, versus a 50% rate seen in traditional options. The drug's Medicare coverage further eases affordability, lowering monthly out-of-pocket costs to $30–$190. Initial demand appears promising, with nearly 500 patients starting treatment in the first two weeks of launch. Even a modest 1% market penetration into the LTC segment could yield $135 million in annual revenue, with $67.5 million in net income assuming 50% margins. A 5% penetration would put net income at $675 million, dwarfing the current valuation. Alpha Cognition has also secured a distribution deal with a major Chinese pharmaceutical firm, creating a royalty-based revenue stream in Asia. While the upside is substantial, key risks remain—most notably, the emergence of unforeseen serious side effects post-launch, which could lead to FDA scrutiny or suspension of sales. Still, the market's underreaction and the company's positioning as a safer, effective alternative in a high-need space make ACOG a high-upside, high-conviction bet for risk-tolerant investors. Previously, we have covered ACOG in March 2025 wherein we summarized a by BullishDoctor on Twitter. The user highlighted that Alpha Cognition Inc.'s drug ZUNVEYL addressed the major side effects of existing Alzheimer's treatments, making it highly tolerable and poised for adoption in long-term care facilities, a $2 billion market. The company was pre-revenue but launched in March 2025 with strong physician support, a nearly complete sales force, and promising catalysts like a Phase 4 study and sublingual formulation, projecting breakeven within three years. Since our last coverage, the stock is up 61% as of 30th May. Alpha Cognition Inc. Common Stock (ACOG) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 8 hedge fund portfolios held ACOG at the end of the first quarter which was 10 in the previous quarter. While we acknowledge the potential of ACOG as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
